Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
More than 15.5 million Americans have tried weight loss injectables, but risks are rising with the proliferation of ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
Utah’s Attorney General Derek Brown signed onto a letter along with attorneys general from 37 other states to ask the Food ...
Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...
Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...
Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...
People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye co ...
Semaglutide — the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy — can expire. If ...
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...